AP NEWS

McKesson Designated as 2019 Qualified Clinical Data Registry by CMS

January 23, 2019

IRVING, Texas--(BUSINESS WIRE)--Jan 23, 2019--McKesson has received approval from the Centers for Medicare and Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) 2019 program year as a Qualified Clinical Data Registry (QCDR). With this designation for the third consecutive year, McKesson will continue to provide clinicians with the ability to report clinical quality measures directly to CMS through data collected within its industry-leading electronic health record (EHR), iKnowMed ℠, for both MIPS and custom non-MIPS quality measures. The integration with iKnowMed, which is oncology-specific and ONC-ACB 2015 Edition Certified, enables practices to drive improvements in quality measure results and reduce the cost of cancer care with no additional documentation, administrative work or need to engage a separate registry vendor.

McKesson’s QCDR supports three MIPS practice-reported categories: Quality; Promoting Interoperability; and Improvement Activities. The fourth category, Cost, is calculated based on CMS claims data, so there is nothing additional for practices to report. In addition to 17 MIPS quality measures, iKnowMed users will also have access to four oncology-specific custom measures identified by physician leaders in The US Oncology Network, all of whom have deep insight into value-based care and community oncology clinical and business operations. All four custom measures are designated as high priority with one also designated as a patient-reported outcome measure. High priority and patient-reported outcome measures are key indicators of quality care. These custom measures allow oncology physicians to report on areas they feel may be more clinically relevant to the way they practice medicine and may help practices maximize their MIPS score and patient outcomes.

“McKesson’s QCDR serves as the foundation to support the transition to value-based care,” said Erin Crum, director of Quality Reporting, McKesson. “Continuous monitoring of key indicators of quality care provides practices with a global view of their adherence to patient care initiatives, such as improving pain management. Through advanced reporting and analytics, practices can achieve successful participation in regulatory programs such as MIPS, and access and interpret data to drive improvements in patient care. As the industry continues to evolve from volume to value, we’re committed to providing practices with the tools necessary to integrate value-based care initiatives into daily practice operations, so they can gain greater insights into patient care and reduce healthcare costs.”

Through McKesson’s QCDR, iKnowMed users gain a wealth of benefits to optimize MIPS performance and value-based care transformation, including:

A comprehensive end-to-end solution for data capture through standard workflow, performance monitoring and direct data submission to CMS Support for 17 MIPS quality measures and four oncology-specific custom QCDR measures A dashboard providing a high-level visualization of MIPS performance and actionable insights for continuous improvement with the ability to drill down by clinician and into patient-specific data

“It’s important for practices to embrace value-based care and invest in the necessary tools to thrive in this new era of healthcare,” said Marcus Neubauer, MD, chief medical officer, McKesson and The US Oncology Network. “Oncologists should look at the shift from volume to value as an opportunity to improve practice operations and efficiency and, more importantly, patient care and outcomes.”

About McKesson Corporation

McKesson Corporation, currently ranked 6 th  on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “ Most Admired Company ” in the healthcare wholesaler category by FORTUNE, a “ Best Place to Work ” by the Human Rights Campaign Foundation, and a top  military-friendly company  by Military Friendly. For more information, visit  www.mckesson.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005126/en/

CONTACT: McKesson

Claire Crye, Public Relations

T 281.825.9927claire.crye@mckesson.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: McKesson Corporation

Copyright Business Wire 2019.

PUB: 01/23/2019 09:00 AM/DISC: 01/23/2019 09:01 AM

http://www.businesswire.com/news/home/20190123005126/en

AP RADIO
Update hourly